Cargando…

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

INTRODUCTION: Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piette, François, Belmin, Joël, Vincent, Hélène, Schmidt, Nicolas, Pariel, Sylvie, Verny, Marc, Marquis, Caroline, Mely, Jean, Hugonot-Diener, Laurence, Kinet, Jean-Pierre, Dubreuil, Patrice, Moussy, Alain, Hermine, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226277/ https://www.ncbi.nlm.nih.gov/pubmed/21504563 http://dx.doi.org/10.1186/alzrt75

Ejemplares similares

Neuroprotective effect of masitinib in rats with postischemic stroke
por: Kocic, Ivan, et al.
Publicado: (2014)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
por: Davidescu, Lavinia, et al.
Publicado: (2022)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
por: Ledoux, Jean-Marie, et al.
Publicado: (2014)

Validation of the French version of the Vulnerable Elders Survey-13 (VES-13)
por: Belmin, Joël, et al.
Publicado: (2020)

Investigation of an Outbreak of COVID-19 in a French Nursing Home With Most Residents Vaccinated
por: Burugorri-Pierre, Catherine, et al.
Publicado: (2021)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline
por: Carment, Loic, et al.
Publicado: (2018)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

Coronavirus Disease 2019 Outcomes in French Nursing Homes That Implemented Staff Confinement With Residents
por: Belmin, Joël, et al.
Publicado: (2020)

Assessment of Frailty by the French Version of the Vulnerable Elders Survey-13 on Digital Tablet: Validation Study
por: Zolnowski-Kolp, Victoria, et al.
Publicado: (2023)

Development of Masitinib Derivatives with Enhanced M(pro) Ligand Efficiency and Reduced Cytotoxicity
por: Menendez, Cintia A., et al.
Publicado: (2023)

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis
por: Hermine, Olivier, et al.
Publicado: (2008)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
por: KATHAWALA, RISHIL J., et al.
Publicado: (2014)

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
por: Drayman, Nir, et al.
Publicado: (2021)

Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry
por: Kadi, Adnan A., et al.
Publicado: (2018)

Masitinib analogues with the N-methylpiperazine group replaced – A new hope for the development of anti-COVID-19 drugs
por: Gurung, Arun Bahadur, et al.
Publicado: (2023)

LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate
por: Amer, Sawsan M., et al.
Publicado: (2017)

Coronavirus Disease 2019 in French Residential Care Facilities: A Nationwide Study
por: Belmin, Joël, et al.
Publicado: (2021)

Open-label placebos as adjunctive therapy for patients with depression
por: Schienle, Anne, et al.
Publicado: (2022)

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
por: Lang, Frederick M., et al.
Publicado: (2021)

Cognitive Stimulation Therapy as an Adjunctive Treatment for Mild to Moderate Dementia
por: Kumar, S. Sandeep, et al.
Publicado: (2023)

A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study
por: Yoosefian, Mehdi, et al.
Publicado: (2023)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ge275s5ecf9b1mpprrg5n74tqb